More articles from Epigenetic Cancer Therapies

Abstract B30: Targeting EZH2 methyltransferase activity: A novel therapeutic approach to ARID1A-deficient cancer
Benjamin Bitler, Azat Garipov, Ie Ming Shih, Rugang Zhang

Cancer Research Jan 2016, 76 (2 Supplement) B30; DOI: 10.1158/1538-7445.CHROMEPI15-B30
Abstract B50: A phenotypic screen to identify novel potential epigenetic anticancer drugs from natural compounds
Hanghang Zhang, Noël J.-M Raynal, Takahiro Sato, Yasuyuki Okamoto, Benjamin Garcia, George Morton, Wayne Childers, Marlene A. Jacobson, Stephen B. Baylin, Magid Abou-Gharbia, Jean-Pierre J. Issa

Cancer Research Jan 2016, 76 (2 Supplement) B50; DOI: 10.1158/1538-7445.CHROMEPI15-B50
Abstract B43: Dose and context-dependent roles for Arid1a in liver tumorigenesis
Xuxu Sun, Sam Wang, Liem Nguyen, Hao Zhu

Cancer Research Jan 2016, 76 (2 Supplement) B43; DOI: 10.1158/1538-7445.CHROMEPI15-B43
Abstract B37: The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly ADP ribose polymerase inhibitors via E2F1 downregulation.
Andrew J. Wilson, Jeanette Saskowski, Dineo Khabele

Cancer Research Jan 2016, 76 (2 Supplement) B37; DOI: 10.1158/1538-7445.CHROMEPI15-B37
Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses
Katherine B. Chiappinelli, Pamela L. Strissel, Alexis Desrichard, Huili Li, Christine Henke, Benjamin Akman, Alexander Hein, Neal S. Rote, Leslie M. Cope, Alexandra Snyder, Vladimir Makarov, Sadna Budhu, Jedd Wolchok, Cynthia A. Zahnow, Taha Mergoub, Timothy A. Chan, Reiner Strick, Stephen B. Baylin

Cancer Research Jan 2016, 76 (2 Supplement) B32; DOI: 10.1158/1538-7445.CHROMEPI15-B32
Abstract B31: EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin lymphoma
William D. Bradley, Chih-Chi Yuan, Feng Zhao, Christina Lee, Kaylyn E. Williamson, Shilpi Arora, Charlie Hatton, Barbara M. Bryant, Patrick Trojer

Cancer Research Jan 2016, 76 (2 Supplement) B31; DOI: 10.1158/1538-7445.CHROMEPI15-B31
Abstract B29: Inhibition of histone deacetylases 1 and 2 (HDAC1,2) perturbs DNA replication and DNA repair in cancer cells: Implications in mechanism-based therapeutic strategies
Danielle Johnson, Simon Jones, Steven Quayle, Jeff Shearstone, Srividya Bhaskara

Cancer Research Jan 2016, 76 (2 Supplement) B29; DOI: 10.1158/1538-7445.CHROMEPI15-B29
Abstract B41: Targeting androgen-independent prostate cancer through epigenetic reprogramming
Loredana Puca, Dong Gao, Myriam Kossai, Joanna Cyrta, Clarisse Marotz, Juan Miguel Mosquera, Theresa Y. MacDonald, Andrea Sboner, Rema Rao, Yu Chen, Mark A. Rubin, Himisha Beltran

Cancer Research Jan 2016, 76 (2 Supplement) B41; DOI: 10.1158/1538-7445.CHROMEPI15-B41
Abstract B28: BET bromodomain inhibitors antagonize Brd4-Mediator complexes to undermine the acute myeloid leukemia cell state
Anand S. Bhagwat, Jae-Seok Roe, Beverly A. Mok, Christopher R. Vakoc

Cancer Research Jan 2016, 76 (2 Supplement) B28; DOI: 10.1158/1538-7445.CHROMEPI15-B28
Abstract B44: Accelerated mouse colorectal cancer progression in the presence of EHMT2 overexpression
Kang-Yu Tai, I-Shing Yu, Shih-Ting Cha, Shu-Wha Lin, Min-Liang Kuo, You-Tzung Chen

Cancer Research Jan 2016, 76 (2 Supplement) B44; DOI: 10.1158/1538-7445.CHROMEPI15-B44

Main menu

User menu

Search

More articles from Epigenetic Cancer Therapies

Pages

Articles

Info for

About Cancer Research